Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Hunan Province Tumor Hospital70 enrolled

Overview

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-squamous NSCLC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel Exclusion Criteria: Patients with contraindication of chemotherapy Pregnant or breast feeding women

Locations (1)

Hunan Cancer Hospital

Changsha, Hunan, China

Outcomes

Primary Outcomes

overall survival

Time frame: September 2019- september 2021

PFS

progression-free survival

Time frame: September 2019- september 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.